Skip to main content

Seroprevalence of hepatitis B and C virus among highly active antiretroviral therapy experienced children in Gondar, Ethiopia



Globally, chronic viral hepatitis is the cause of mortality alongside human immunodeficiency virus/acquired immunodeficiency syndrome and tuberculosis. Published reports on the seroprevalence of hepatitis B and C viruses among HIV-infected children are lacking in sub-Saharan Africa. Hence, this study aimed to determine the seroprevalence of hepatitis B and C viruses among highly active antiretroviral therapy (HAART)-experienced children at the University of Gondar Comprehensive Specialized Hospital.


We conducted a hospital-based cross-sectional study to determine the seroprevalence of hepatitis B and C viruses among HAART-experienced children from January to May 2020. We collected the socio-demographic characteristics of study participants with pretested questioners and clinical data from medical records. We performed enzyme-linked immunosorbent assay-based laboratory test for serum hepatitis B surface antigens and anti-hepatitis C virus antibodies. Finally, we analyzed the frequency of all variables, determined the association of independent variables with hepatitis B and C viruses by using univariable and then multivariable logistic regression.


A total of 241 HAART-experienced children were enrolled, 49.8% of whom were girls. The median age of participants was 13 years (interquartile range 11–14). The seroprevalence of hepatitis B and C virus infection among HAART-experienced children were 9.5% and 2.9%, respectively. Being underweight was significantly associated with both hepatitis B virus (AOR = 3.87: 95% CI; 1.04–14.46, P = 0.044) and hepatitis C virus infections (AOR = 4.54: 95% CI; 1.21–17.04, P = 0.025).


This study showed that the magnitude of hepatitis B and C viruses was high among HIV-infected children who were under HAART and did not know their hepatitis B and C infection status before. Being underweight was associated with both hepatitis viruses. Therefore, screening for hepatitis B and C viruses should be a routine measure for all HIV-infected children.


Viral hepatitis is a global health issue that claims the lives of 1.34 million people each year. This is more than the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) related mortality of 1 million and upcoming to 1.67 million tuberculosis-related mortality in a single year [1,2,3]. Chronic liver disease associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) is becoming a significant cause of morbidity and mortality among people living with HIV [4]. All three of these viruses share a similar route of transmission [5], such as unsafe sexual contact, blood and blood products, vertical transmission (mainly HBV), horizontal (child-to-child) and injections (mainly HCV) [6] and are preventable; HCV is curable [7].

An estimated 37.7 million people are living with HIV, more than two-thirds of whom dwell in sub-Saharan Africa (SSA) [8]. Among these, 2.7 million are co-infected with HBV and 2.3 million with HCV [9]. According to Barth et al., the rate of HBV infection among people living with HIV (PLWHIV) in Africa is 15%, while HCV infection is 7% [10]. Hepatitis B and C viruses are the common causes of mortality from chronic liver disorders such as Hepatocellular Carcinoma (HCC) and cirrhosis. In SSA, HBV is the common cause of HCC, with 36,700 HCC-related deaths in 2020, and this death rate is expected to double by 2040 [11].

Before the implementation of HAART, coinfection of HIV with HBV and HCV increased mortality [12, 13]. Moreover, HBV infection increases the hepatotoxicity of HAART [14]. Even among HAART-initiated HIV patients, chronic HBV and HCV infections are increasing health challenges [15]. Untreated HIV–hepatitis coinfection, according to the World Health Organization (WHO), hastens progression of HBV and/or HCV–related liver disease, HCC impeding effective HIV treatment [9].

Access to HBV immunization may be lower in HIV-infected infants, or a full dose vaccination may not be protective, and they may be infected by HBV, as a result of a weaker immunologic response and declining titer of antibodies against hepatitis B surface antigens (HBsAg). Besides, the risk of developing chronic hepatitis is about 90% if HBV is acquired during birth or soon after birth, compared to a lower (5%) risk when the infection is acquired in adulthood [16]. Children in SSA are at increased risk of HBV and HCV because home birth is common (> 40%), which increases the risk of perinatal transmission, limits access to HBV vaccination, and needs special attention [17].

In SSA, resources for establishing laboratories with reliable diagnostic tools are limited, which sets back the WHO’s end viral hepatitis target [1]. The prevalence of HBV and HCV infection in HIV-infected children varies significantly with geographic areas and remains to be determined [18]. Those few studies conducted in SSA confirm this, revealing 5.3% in Nigeria and 15% in Tanzania [19, 20]. The Ethiopian Federal Ministry of Health (FMOH) has included HBV vaccination in its Expanded Program of Immunization (EPI) and set a goal of using aggregated national data for evidence-based decisions towards ending viral hepatitis [21]. Published reports on HIV, HBV, and HCV coinfection in children are scarce in the country, even in SSA [22] and lacking in the study area, so determining the local prevalence of these viruses in this segment of population will be the basis for establishing pooled figures in the country. The result will guide health managers, including the Ethiopian FMOH, to give due attention and design effective treatment and control policies. Therefore, this study aimed to provide figures of the seroprevalence and associated factors of HBV and HCV among HAART-experienced children at the University of Gondar Comprehensive Specialized Hospital (UoGCSH).

Materials and methods

Study design and area and period

We conducted a cross-sectional study at the UoGCSH ART clinic from January to May 2020 among HAART-experienced HIV-infected children. The hospital is one of the oldest teaching hospitals and is found in the historic town of Gondar, 740 km away from Addis Ababa, the capital city of Ethiopia. The hospital has been providing different health services such as medical, surgical and many other services in both inpatient and outpatient settings for more than 7 million people from Gondar province and neighboring regions. It launched a free-of-charge HIV/AIDS intervention services and has been providing free diagnosis, treatment, and monitoring in its ART clinic for both pediatric and adult patients since 2003.

Study population

We included 241 HAART-experienced children in this study by using a convenient, non-probabilistic sampling technique. We systematically included all the participants in the study consecutively until the end of the study period (May-2020). This study included all under 15-year-old HIV-infected children attending their follow-up at the UoGCSH, taking HAART and did not know their HBV and HCV status and had no known history HBV vaccination during the study period (Fig. 1).

Fig. 1
figure 1

The flow diagram of the inclusion process of study participants

Data collection and laboratory procedures

We collected the socio-demographic characteristics of children, including age, gender, residence, educational status, family income, family size, and family occupation by using pretested and structured questioners via a face-to-face interview. Moreover, we gathered the detailed clinical data of the children such as WHO HIV disease stage at the time of sample collection, type of HAART, and duration of HAART they had been taking at the time of sample collection, by reviewing the medical records of HIV-infected children. Based on the WHO guidelines, the most commonly prescribed HAART regimen consists of nucleoside reverse transcriptase inhibitors (NRTIs: lamivudine (3TC), abacavir (ABC), and zidovudine (AZT), tenofovir disoproxil fumarate (TDF)) together with a non-nucleoside reverse transcription inhibitor (NNRTI, nevirapine or efavirenz) or a protease inhibitor (lopinavir). Currently, the preferred HAART regimen for those children is the release of a new, dispersible tablet formulation of dolutegravir (DTG) plus two nucleoside reverse transcriptase inhibitors (NRTIs) [23]. As the study participants were HIV-infected children, WHO anthro (for children aged ≤ 5 years) and anthro-plus (for children aged > 5 years) software were applied for calculation of their anthropometric measures such as Z-scores of Weight-for-Age (WAZ), Height-for-Age (HAZ) and Body Mass Index for Age (BAZ) based on WHO nutritional assessment guideline. Underweight children are those whose z-score of weight-for-age (WAZ) is less than − 2, while stunted means children who have lower than height-for-age of less than − 2 Z-scores [24].

Regarding the laboratory method, 5 ml of venous blood was collected following standard operating procedures (SOPs) for HIV-viral load determination, centrifuged to extract serum for the analysis of HBsAg and anti-HCV antibodies using enzyme-linked immunosorbent assay (ELISA). The serum specimen was stored at – 80 °C until processed and brought to room temperature and analyzed by thawing once before analysis. Then, the HBsAg and anti-HCV antibody (IgG and IgM) were detected on sera using ELISA according to the manufacturer’s instructions using AiD™ HBsAg ELISA and Wantai Aid™ anti-HCV ELISA Plus, ELISA kits (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, China). Furthermore, HIV Ribonucleic acid (RNA) viral load was determined directly by an advanced molecular technique using TAQMAN® AMPLICOR HIV-1 MONITOR (Roche Molecular Systems) according to the manufacturer's instruction by well-trained laboratory technologists. To ensure the quality of data, pre-analytical, analytical, and post-analytical phases were strictly maintained. Safety procedures and specimen handling procedures were strictly followed for the tests. (ELIZA, and HIV viral load). The manufacturer procedures and SOPs were strictly followed.

Data analysis and interpretation

Data were coded and entered into EPI-info version 4.4 and were transferred to Statistical Package for Social Science (SPSS) version 20 for analysis. Descriptive statics like frequencies and percentages were used to summarize the results. The distribution of data was assessed through Shapiro–Wilk test and a p-value > 0.05 in the Shapiro–Wilk test was considered as normally distributed data. Both crude odds ratio (COR) and adjusted odds ratio (AOR) with 95% confidence interval (CI) were calculated to determine the extent to which the risk factors are associated with hepatitis infection. Variables such as sex, age, WAZ grouped, BAZ grouped, HAZ grouped, educational status, family marital status, family educational status, family size, lymphopenia, anemia, WHO HIV stage, HIV viral load were subjected to univariable analysis for calculating COR. To identify the independent factors, variables with p < 0.2 at univariable analysis were included in multivariable analysis. The model was built by dropping the most insignificant factors one at a time in a stepwise manner and finally, in the multivariable analysis, a variable with a p-value < 0.05 was considered as statistically significant.


Socio-demographic and clinical characteristics of HAART-experienced children

The total number of study participants in the study was 241, of whom 121 (50.2%) were boys. Among these study participants, 86.7% had been taking the HAART for a year or longer. The median age of participants was 13 years, with an interquartile range (IQR)-of 11–14. In addition, 232 (96.4%), 52 (21.6%), and 204 (84.6%) of the participants were in the WHO clinical stage of HIV-I, had an HIV viral load of above 1000 (both at the time of data collection), and had been living with HIV-infected parents, respectively. All 241 of the study participants were on ART regimens that contain 3TC in its backbone. The overall seroprevalence of HBsAg and anti-HCV Abs among HAART-experienced children who did not know their HBV and/or HCV infection status before, was 12.4% (95% CI = 8.7–17). The seroprevalence of HBsAg was 9.5% (N = 23, 95%CI: 6.6–13.2), and anti-HCV Abs were 2.9% (N = 7, 95% CI = 0.8–5.8). There was no coinfection of HBV and HCV in this study (Table 1).

Table 1 Socio-demographic and clinical characteristics of HAART experienced children at the UoGCSH, 2020

The association of socio-demographic features of HAART-experienced children with HBV infection

Among the variables computed in univariable logistic regression to determine the association with HBsAg seropositivity, weight (WAZ) (COR = 3.96: 95% CI; 1.15–13.65 and P = 0.029) and HIV-viral load (COR = 3.14: 95% CI; 1.10–8.97 and P = 0.033) were entered to and analyzed in multivariable analysis. The result of multivariable analysis revealed that WAZ was significantly associated with HBsAg seropositivity (AOR = 3.87: 95% CI; 1.04–14.46, and P = 0.044) (Table 2).

Table 2 Factors associated with HBV infection among HAART experienced children at the UoGCSH, 2020

The association of socio-demographic and clinical features of HAART-experienced children with HCV infection

Regarding the association variables with anti-HCV seropositivity, the variable WAZ showed a statistically significant association with HCV infection (AOR = 4.54: 95% CI; 1.21–17.04 and P = 0.025) (Table 3).

Table 3 Factors associated with HCV infection among HAART-experienced children at the UoGCSH, 2020


The World Health Organization designed a strategy for eliminating viral hepatitis as part of the Global Health Sector Strategy (GHSS) agenda 2030 for sustainable development. It aimed to succeed in diagnosing 90% of infected individuals, treating 80% of diagnosed cases, reducing death by 65%, and vaccinating 90%. Unfortunately, less than 5% of chronic viral hepatitis patients know their status. Knowledge of the burden of HBV and HCV and incorporation of the target population who needs the services in each country are two of the five strategic directions for the GHSS goal [1]. Therefore, this study reveals the seroprevalence of HBV and HCV among HIV-infected children (the population who need the services), which supports determining the national prevalence of viral hepatitis in this population segment.

All the study participants received ART containing 3TC in the backbone as the Ethiopian HIV treatment guidelines recommended. Lamivudine (3TC) is also active against HBV and is commonly used in the treatment of HBV or combined with other drugs for the treatment of HIV or HIV–HBV [25]. The 3TC is accessible at a lower cost in resource-limited settings like Ethiopia [26]. The national HIV treatment guideline requests screening for baseline HBV serology (HBsAg) [25] But HBV diagnosis before initiation of HIV treatment and close monitoring of patients on for HBV viremia and biochemical status are not implemented in Ethiopia. Mutation and rapid progression of drug resistance, exacerbation of HBV disease and liver enzyme flare are the potential risks in this high HIV/HBV burden area [26, 27]. This study did not assess the effect of 3TC because all the study participants were exposed to the drug, tested once and not followed for HBV response.

The overall seropositivity rate of hepatitis among HAART-experienced children was 12.4% (95% CI = 8.7–17). From these, 9.5% were seropositive for HBsAg and the rest 2.9% were seropositive for anti-HCV antibodies. The overall result was comparable to the seropositivity rate of both HBsAg and anti-HCV reported in Nigeria (14.0%) [28]. The result was also analogous to results reported in Guinea, (HBsAg = 8.16%) [29], Sierra Leone (HBsAg = 7.4% and anti-HCV = 1.5%) among children receiving ART[30];Tanzania (HBsAg = 7%) [31], Rwanda (HBsAg = 7%) [32], and Nigeria (HBsAg = 10% and anti-HCV = 1.7%) among ART-naïve HIV-infected children [33]. The SSA is a region of high HBV endemicity (8% and above) [34]. The result of our study indicates that the seroprevalence of HBV and HCV is high among children who are taking HAART.

The result of this study reveals a higher positivity rates of HBsAg compared to results reported by investigators from West Africa (2.2–5.3%) [20, 35,36,37,38] and comparable positivity rates of anti-HCV (0.5–3.9%) results from the same region [20, 37, 39].

The variation might be because of population and geographic differences. Some authors included infants, while others included those adolescents who were aged above 15 years old. But, in this study, children aged 2 to 15 years old were the study population. Efforts to ensure health care, expand HBV vaccination programs, and the goal of ending viral hepatitis might also be responsible for the difference. The result of this study indicates that Ethiopia is far behind the goal set by the WHO to end viral hepatitis by 2030 [40]. The WHO recommendations for routine screening of HIV patients for HBV and HCV infections were not implemented in Ethiopia, in which resources are limited, and the result of our study reflects this weak move towards the target [41].

Unlike the result of this study, a study involving ART-naïve HIV-infected children in Bahir Dar, Ethiopia, reported a reduced seroprevalence of HBV (HBsAg = 2%) and a borderline higher HCV (anti-HCV = 5.5%) [18]. In addition, a study done in Nigeria reported a lower HBV (HBsAg = 3%) and a higher HCV (anti-HCV = 11%) infection among HAART-experienced children [28]. The difference in the length of exposure to HAART and anti-HBV activity of the regimens could have reduced HBV infection. In contrast, the higher HCV infection rate might be attributed to weak immune reconstitution in these children. Hepatitis C virus coinfection in HAART-experienced HIV patients has been shown to have a low immune/CD4 reconstitution [18, 41].

Among the variables analyzed in this study, weight was the variable significantly associated with HBV and HCV infections. The likelihood of HBV seropositivity in HAART-experienced underweight children was nearly fourfold higher than the likelihood of HBV seropositivity in normal-weight children (AOR = 3.87). Similarly, the odds of HCV seropositivity among underweight (WAZ) children was at least 4.5 times higher than the odds of HCV among normal-weight children. The higher likelihood of hepatitis seropositivity among underweight children might be associated with poor nutritional status and associated poor immune status or immunosuppression by HIV infection, and the resulting lower clearance capacity for the viruses. Strengths of this research: this research focused on the high-risk population segment. Hence, it can be an example of the local prevalence of HBV and HCV among HAART experienced children living with HIV in the high burdened SSA region. We included large sample size and ELISA rather than rapid diagnostic techniques for detection. It can also be used as baseline data for further study and control strategy. This study was limited by the lack of data on the history of vaccination, absence of HBV-core antibody tests and molecular tests for detection HBV and HCV, lack of longitudinal data and absence of liver function tests. There were two children who had history of vaccination and were excluded.


The findings of this study showed that the seroprevalence of hepatitis B and C virus infection was high among HAART-experienced children with unknown previous hepatitis status. The variable being underweight was associated with both hepatitis B and C viruses. Therefore, screening HIV-infected children and implementing appropriate remedial measures are crucial to reducing these infections. Large-scale population-based studies on are needed to determine the national prevalence to help reach the WHO end viral hepatitis goal by 2030.

Availability of data and materials

All data generated and analyzed during this study were included in this article. Data supporting the findings of this study are also available at the corresponding author for a reasonable request.



Adjusted odds ratio


Antiretroviral therapy


Body Mass Index for Age Z-score


Confidence interval


Crude odds ratio


Enzyme linked immunosorbent assay


Highly active antiretroviral therapy


Height-for-Age Z-score


Hepatitis B surface antigen


Hepatitis B virus


Hepatocellular carcinoma


Hepatitis C virus


Human immunodeficiency virus/acquired immunodeficiency syndrome


People living with HIV


Sub-Saharan Africa


University of Gondar Comprehensive Specialized Hospital


Weight-for-Age Z-score


World Health Organization Global Health Sector Strategy


  1. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. World Health Organization, 2016.

  2. Unaids J. Fact sheet—latest global and regional statistics on the status of the AIDS epidemic. Geneva: UNAIDS; 2017.

    Google Scholar 

  3. World Health Organization. Global hepatitis report 2017: World Health Organization; 2017.

  4. Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 M ortalité 2010 survey. HIV Med. 2015;16(4):230–9.

    Article  CAS  Google Scholar 

  5. Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol. 2017;27(14):R713–5.

    Article  CAS  Google Scholar 

  6. World Health Organization. Management of hepatitis B and HIV coinfection, Clinical Protocol for the WHO European Region 2011 revision. 2011.

  7. Singh PK. Towards ending viral hepatitis as a public health threat: translating new momentum into concrete results in South-East Asia. Gut Pathogens. 2018;10(1):1–5.

    Article  Google Scholar 

  8. World Health Organization. HIV/AIDS _Fact sheet 2020 Accessed 2020.

  9. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact: web annex 2: data methods. 2021.

  10. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14(12):e1024–31.

    Article  Google Scholar 

  11. Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27(36):6025.

    Article  Google Scholar 

  12. Miailhes P, Trabaud M-A, Pradat P, Lebouché B, Chevallier ML, Chevallier P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis. 2007;45(5):624–32.

    Article  Google Scholar 

  13. Sadoh A, Sadoh W, Iduoriyekemwen N. HIV co-infection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme. S Afr J Child Health. 2011;5(1):7–10.

    Article  Google Scholar 

  14. Ayuk J. Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART. S Afr Med J. 2013;103(5):330–3.

    Article  CAS  Google Scholar 

  15. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55(suppl_1):S33–42.

    Article  CAS  Google Scholar 

  16. Healy SA, Gupta S, Melvin AJ. HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther. 2013;11(3):251–63.

    Article  CAS  Google Scholar 

  17. World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy: web annex A: systematic review of the efficacy and safety of antiviral therapy during pregnancy. 2020.

  18. Abera B, Zenebe Y, Mulu W, Kibret M, Kahsu G. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia. BMC Res Notes. 2014;7(1):1–6.

    Article  Google Scholar 

  19. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment Center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007;7(1):1–6.

    Article  Google Scholar 

  20. Lawal MA, Adeniyi OF, Akintan PE, Salako AO, Omotosho OS, Temiye EO. Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria. PLoS ONE. 2020;15(12): e0243656.

    Article  CAS  Google Scholar 

  21. Ministry of Health Ethiopia. National Strategy for Prevention and Control of Viral Hepatitis 2016–2020. 2016.

  22. Tamandjou Tchuem CR, Brandt L, Nel EDLR, Cotton MF, Matthews P, Kaindjee-Tjituka F, et al. Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. PLoS ONE. 2020;15(9): e0238839.

    Article  CAS  Google Scholar 

  23. World Health Organization. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2021.

  24. World Health Organization. Guideline: updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013.

    Google Scholar 

  25. Ministry of health Ethiopia. National consolidated guidelines for comprehensive HIV prevention. Care and Treatment. 2018.

  26. Ocama P, Seremba E, Apica B, Opio K. Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda. Afr Health Sci. 2015;15(2):328–33.

    Article  Google Scholar 

  27. Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Marrone G, Grossmann S, et al. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. BMC Infect Dis. 2019;19(1):1–10.

    Article  CAS  Google Scholar 

  28. Pennap G, Yahuza A, Abdulkarim M, Oti V. Prevalence of Hepatitis B and C viruses among human immunodeficiency virus infected children attending an antiretroviral therapy clinic in Lafia, Nigeria. Asia J Appl Microbiol. 2016;3(4):38–43.

    Article  Google Scholar 

  29. Kaba D, Bangoura MA, Sylla MM, Sako FB, Diallo MS, Diallo I, et al. Prevalence and factors associated with hepatitis B in a cohort of HIV-infected children in the Pediatric Department at Donka National Hospital, Guinea. Pan Afr Med J. 2019;34(182):335.

    Article  Google Scholar 

  30. Yendewa GA, Lakoh S, Yendewa SA, Bangura K, Lawrence H, Patiño L, et al. Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: a cross-sectional study. Int J Infect Dis. 2021;102:45–52.

    Article  CAS  Google Scholar 

  31. Muro FJ, Fiorillo SP, Sakasaka P, Odhiambo C, Reddy EA, Cunningham CK, et al. Seroprevalence of hepatitis B and C viruses among children in Kilimanjaro Region, Tanzania. J Pediatr Infect Dis Soc. 2013;2(4):320–6.

    Article  Google Scholar 

  32. Mutwa PR, Boer KR, Rusine JB, Muganga N, Tuyishimire D, Reiss P, et al. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J. 2013;32(3):246–51.

    Article  Google Scholar 

  33. Durowaye M, Ernest S, Ojuawo I. Prevalence of HIV co-infection with Hepatitis B and C viruses among children at a tertiary hospital in Ilorin, Nigeria. Int J Clin Med Res. 2014;1:42–7.

    Google Scholar 

  34. Weldemhret L. Epidemiology and challenges of HBV/HIV co-infection amongst HIV-infected patients in endemic areas. HIV/AIDS (Auckland, NZ). 2021;13:485.

    Article  Google Scholar 

  35. Varo R, Chris Buck W, Kazembe PN, Phiri S, Andrianarimanana D, Weigel R. Seroprevalence of CMV, HSV-2 and HBV among HIV-infected Malawian children: a cross-sectional survey. J Trop Pediatr. 2016;62(3):220–6.

    Article  Google Scholar 

  36. Joseph F, Rodrigue KW, Serges T, Salomon NP, Christian TN, Carlos TTM, et al. Hepatitis B infection and risk factors among children living with HIV in Yaounde, Cameroon: an integrated management. BMC Pediatr. 2019;19(1):1–8.

    Article  CAS  Google Scholar 

  37. Okechukwu A, Thairu Y, Dalili M. HIV co-infection with hepatitis B and C and liver function in children and adolescents on antiretroviral therapy in a tertiary health institution in Abuja. West Afr J Med. 2020;37(3):260–7.

    CAS  Google Scholar 

  38. Toyé RM, Lô G, Diop-Ndiaye H, Cissé AM, Ndiaye AJS, Kébé-Fall K, et al. Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal. Clin Res Hepatol Gastroenterol. 2021;45(2): 101502.

    Article  CAS  Google Scholar 

  39. Onyire NB, Orji ML, Ogah EO. Prevalence of Hepatitis B and C Infections in children infected with human immunodeficiency virus in Abakaliki, Ebonyi State, Southeast, Nigeria. Malay J Paediatr Child Health. 2017;23(1):51–8.

    Google Scholar 

  40. World Health Organization. End hepatitis by 2030: prevention, care and treatment of viral hepatitis in the African Region: framework for action, 2016–2020. 2017.

  41. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. World Health Organization. 2010.

Download references


We the authors acknowledge the study participants and University of Gondar Hospital.


We declare that this study had no external financial support.

Author information

Authors and Affiliations



BB: contributed to conceptualized and methodological aspects, MW: participated in metrological aspects of the study and formal analysis and DK: contributed in conceptualized, formal analysis and wrote the first draft of the manuscript. All the authors agreed and are responsible for this manuscript publication. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Desie Kasew.

Ethics declarations

Ethics approval and consent to participate

Research and Ethics Review Committee of the School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar approved ethically before conducting research. In accordance with the declaration of Helsinki, written informed consent was signed by all parents/caretakers and assent was sought from children > 7 years. Those positive children were connected with physicians.

Consent for publication

Not applicable.

Competing interests

All authors declare no conflict of interest with respect to the authorship and/or publication of this research paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kasew, D., Wondmagegn, M. & Bayleyegn, B. Seroprevalence of hepatitis B and C virus among highly active antiretroviral therapy experienced children in Gondar, Ethiopia. Trop Med Health 50, 97 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: